Virios Therapeutics (NASDAQ:VIRI) Shares Down 9.7% – Should You Sell?

Virios Therapeutics, Inc. (NASDAQ:VIRI)’s share price was down 9.7% during trading on Thursday . The company traded as low as $2.40 and last traded at $2.41. Approximately 14,466 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 1,049,645 shares. The stock had previously closed at $2.67.

Analyst Ratings Changes

Separately, HC Wainwright raised their price target on Virios Therapeutics from $0.20 to $5.00 and gave the stock a “neutral” rating in a report on Wednesday, October 9th.

Virios Therapeutics Stock Down 2.1 %

The firm has a market capitalization of $45.45 million, a price-to-earnings ratio of -8.93 and a beta of 1.58. The company’s 50 day moving average price is $3.28 and its 200 day moving average price is $1.28.

About Virios Therapeutics

Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.